港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

藥捷安康-B

10.210

+0.2352.36%

成交量：442.40萬

成交額：4,476.71萬

市值：41.55億

市盈率：-11.52

高：10.300

開：10.030

低：9.805

收：9.975

52周最高：679.500

52周最低：9.010

股本：4.07億

香港流通股本：3.12億

量比：0.58

換手率：1.42%

股息：- -

股息率：- -

每股收益(LYR):-0.886

淨資產收益率：-62.88%

總資產收益率：-32.06%

市淨率：8.56

市盈率(LYR):-11.52

市銷率: - -

資料載入中...

總覽公司新聞資訊公告

藥捷安康-B：Morningside Venture (I) Investments Limited減持，好倉比例降至5.76%

藥捷安康-B（02617）公告將於2026年8月26日召開董事會審議中期業績

藥捷安康-B：CS Capital Co., Ltd.（國投招商投資管理有限公司）減持，好倉比例降至5.85%

藥捷安康-B：先進製造產業投資基金二期減持，好倉比例降至5.85%

從0到1，藥捷安康-B（2617.HK）替恩戈替尼上市，以「全球首創」開啓商業化元年

藥捷安康首款創新藥獲批，去年股價曾暴升逾600港元，如今已跌破發行價

红星资本局

藥捷安康-B早盤升逾12% 核心產品替恩戈替尼片獲批上市

異動解讀｜藥捷安康-B盤中上漲21.51%，核心產品捷恩泰獲NMPA附條件批准上市

港股異動 | 藥捷安康-B(02617.HK)高開近15% 核心產品替恩戈替尼片獲批上市

藥捷安康-B(02617)：捷恩泰®(替恩戈替尼片)獲國家藥品監督管理局批准上市

藥捷安康-B（02617）自主創新藥捷恩泰獲NMPA附條件上市批准

Genecare Development Limited減持藥捷安康-B(02617)46.75萬股每股作價約12.58港元

藥捷安康-B：Morningside Holdings (Asia) Limited減持，好倉比例降至6.87%

藥捷安康-B：Morningside Venture (I) Investments Limited減持，好倉比例降至6.87%

藥捷安康-B：Morningside Bio-Ventures Limited減持，好倉比例降至6.87%

藥捷安康-B：Ghalibo (PTC) Limited減持，好倉比例降至6.87%

藥捷安康-B：陳譚慶芬減持，好倉比例降至6.87%

藥捷安康-B：Genecare Development Limited減持，好倉比例降至6.87%

異動解讀｜藥捷安康-B盤中上漲5.08%，密集回購疊加多管線臨床進展推動股價延續反彈

異動解讀｜藥捷安康-B盤中上漲8.83%，港股創新藥板塊持續走強疊加公司密集回購

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/stock/02617/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02617","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"藥捷安康-B","latestPrice":10.21,"timestamp":1787644231652,"preClose":9.975,"halted":0,"volume":4424000,"delay":0,"changeRate":0.02355889724310789,"floatShares":312000000,"shares":407000000,"eps":-0.8861434024974328,"marketStatus":"交易中","change":0.235,"latestTime":"08-25 15:51:26","open":10.03,"high":10.3,"low":9.805,"amount":44767072,"amplitude":0.049624,"askPrice":10.21,"askSize":10000,"bidPrice":10.2,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-0.8856233762375461,"tradingStatus":2,"nextMarketStatus":{"tag":"收盤","tradingStatus":0,"beginTime":1787645400000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":9.975,"openAndCloseTimeList":[[1787621400000,1787630400000],[1787634000000,1787644800000]],"volumeRatio":0.580775,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02617\",,,,,undefined,":{"symbol":"02617","floatShares":312000000,"roa":"-32.06%","roe":"-62.88%","lyrEps":-0.886095,"volumeRatio":0.580775,"shares":407000000,"dividePrice":0,"high":10.3,"amplitude":0.049624,"preClose":9.975,"low":9.805,"week52Low":9.01,"pbRate":"8.56","week52High":679.5,"institutionHeld":0,"latestPrice":10.21,"committee":0.02439,"eps":-0.8860947543348071,"divideRate":0,"volume":4424000,"delay":0,"ttmEps":-0.8855747566237105,"open":10.03,"prevYearClose":114.9,"prevWeekClose":10.31,"prevMonthClose":9.95,"prevQuarterClose":11.55,"fiveDayClose":10.16,"twentyDayClose":9.78,"sixtyDayClose":35.02,"earningDate":1787673600000},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02617\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787707800000,"name":null,"time":"","dateTimestamp":1787673600000,"actualEps":null},{"market":"HK","date":"2026-03-31","symbol":"02617","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1774886400000,"reportTimeType":"post","actualEps":null},{"date":"2025-08-25","symbol":"02617","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756085400000,"name":null,"time":"","dateTimestamp":1756051200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02617\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02617\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02617\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02617","date":"2026-08-24","current":-11.528603,"percent":0.979167,"low":-380.446233,"twenty":-208.418403,"median":-81.335146,"eighty":-38.321611,"high":-10.87103,"avg":-114.401575,"sd":96.211015,"marketCap":4068988364},"quantilePoints":[{"date":"2025-06-20","current":-17.403134,"twenty":-17.403134,"median":-17.403134,"eighty":-17.403134,"marketCap":5219203873},{"date":"2025-06-27","current":-36.622688,"twenty":-34.709071,"median":-32.493198,"eighty":-31.066553,"marketCap":11013909315},{"date":"2025-07-04","current":-44.802949,"twenty":-38.622694,"median":-35.660049,"eighty":-31.776499,"marketCap":13474674640},{"date":"2025-07-11","current":-39.630155,"twenty":-40.38446,"median":-38.336544,"eighty":-32.816725,"marketCap":11906928990},{"date":"2025-07-18","current":-43.957869,"twenty":-42.111612,"median":-39.630155,"eighty":-34.373739,"marketCap":13196846297},{"date":"2025-07-25","current":-49.067594,"twenty":-42.195906,"median":-40.285196,"eighty":-36.230637,"marketCap":14784436829},{"date":"2025-08-01","current":-50.963195,"twenty":-45.655878,"median":-41.371359,"eighty":-36.620356,"marketCap":15260713988},{"date":"2025-08-08","current":-58.015216,"twenty":-51.234741,"median":-42.017389,"eighty":-37.993773,"marketCap":17415868136},{"date":"2025-08-15","current":-66.867935,"twenty":-57.065221,"median":-42.261724,"eighty":-38.707864,"marketCap":20043330466},{"date":"2025-08-22","current":-72.723484,"twenty":-59.09189,"median":-43.957869,"eighty":-39.464263,"marketCap":21730145406},{"date":"2025-08-29","current":-49.610789,"twenty":-64.458089,"median":-47.896219,"eighty":-39.630155,"marketCap":21492006826},{"date":"2025-09-05","current":-57.867887,"twenty":-63.405379,"median":-50.300475,"eighty":-39.739866,"marketCap":25044240642},{"date":"2025-09-12","current":-176.221101,"twenty":-67.557018,"median":-51.642061,"eighty":-40.181616,"marketCap":76402794352},{"date":"2025-09-19","current":-137.321051,"twenty":-71.134174,"median":-54.042597,"eighty":-40.68225,"marketCap":59494955186},{"date":"2025-09-26","current":-219.814439,"twenty":-72.736767,"median":-55.62397,"eighty":-41.23574,"marketCap":56835741045},{"date":"2025-10-03","current":-208.418403,"twenty":-113.88308,"median":-57.213624,"eighty":-41.375772,"marketCap":54017767851},{"date":"2025-10-10","current":-183.264838,"twenty":-172.633767,"median":-57.790453,"eighty":-41.583173,"marketCap":47429267143},{"date":"2025-10-17","current":-311.562728,"twenty":-178.967921,"median":-58.015216,"eighty":-41.927636,"marketCap":80570219499},{"date":"2025-10-24","current":-293.038662,"twenty":-206.454369,"median":-63.574223,"eighty":-42.029097,"marketCap":75807447903},{"date":"2025-10-31","current":-281.572204,"twenty":-212.338922,"median":-65.741367,"eighty":-42.067733,"marketCap":72949784945},{"date":"2025-11-07","current":-338.772318,"twenty":-240.199465,"median":-68.232426,"eighty":-42.195906,"marketCap":87714376893},{"date":"2025-11-14","current":-312.135011,"twenty":-262.893893,"median":-70.289151,"eighty":-42.482614,"marketCap":81046496658},{"date":"2025-11-21","current":-312.892206,"twenty":-281.392507,"median":-71.392356,"eighty":-43.133487,"marketCap":81205255711},{"date":"2025-11-28","current":-305.66478,"twenty":-292.6573,"median":-72.756691,"eighty":-44.126885,"marketCap":79617665179},{"date":"2025-12-05","current":-292.058382,"twenty":-294.387608,"median":-99.507708,"eighty":-45.187328,"marketCap":76204345536},{"date":"2025-12-12","current":-243.995471,"twenty":-293.167092,"median":-152.573856,"eighty":-47.193393,"marketCap":63781449623},{"date":"2025-12-19","current":-248.269013,"twenty":-292.997062,"median":-174.177612,"eighty":-49.176233,"marketCap":65051522048},{"date":"2025-12-24","current":-196.609225,"twenty":-292.87226,"median":-176.029803,"eighty":-49.50215,"marketCap":51676071816},{"date":"2026-01-02","current":-170.268162,"twenty":-292.367293,"median":-176.029803,"eighty":-50.024601,"marketCap":44928812055},{"date":"2026-01-09","current":-172.395935,"twenty":-291.502465,"median":-173.687618,"eighty":-50.606284,"marketCap":45603538031},{"date":"2026-01-16","current":-142.824051,"twenty":-290.689477,"median":-172.622298,"eighty":-50.90198,"marketCap":37903723951},{"date":"2026-01-23","current":-125.658859,"twenty":-289.035292,"median":-170.268162,"eighty":-51.777834,"marketCap":33316302355},{"date":"2026-01-30","current":-123.813683,"twenty":-286.862177,"median":-169.566856,"eighty":-52.840115,"marketCap":32977154367},{"date":"2026-02-06","current":-105.494623,"twenty":-283.350344,"median":-167.82666,"eighty":-53.700055,"marketCap":28169232889},{"date":"2026-02-13","current":-102.143547,"twenty":-281.033113,"median":-142.637109,"eighty":-54.549461,"marketCap":27431087268},{"date":"2026-02-20","current":-99.091969,"twenty":-280.673719,"median":-140.820404,"eighty":-54.88737,"marketCap":26573242357},{"date":"2026-02-27","current":-101.401985,"twenty":-277.873293,"median":-135.446139,"eighty":-55.077905,"marketCap":27490936913},{"date":"2026-03-06","current":-136.499284,"twenty":-268.489172,"median":-127.818396,"eighty":-56.170035,"marketCap":36707782236},{"date":"2026-03-13","current":-113.20329,"twenty":-265.946326,"median":-125.658859,"eighty":-56.966285,"marketCap":30583168569},{"date":"2026-03-20","current":-101.699451,"twenty":-264.885138,"median":-122.419285,"eighty":-57.460964,"marketCap":27371237623},{"date":"2026-03-27","current":-103.891016,"twenty":-259.5894,"median":-118.720319,"eighty":-57.713018,"marketCap":27889934546},{"date":"2026-04-02","current":-103.689961,"twenty":-256.279611,"median":-116.735022,"eighty":-57.836913,"marketCap":27969734073},{"date":"2026-04-10","current":-80.663784,"twenty":-255.242863,"median":-113.754326,"eighty":-57.879207,"marketCap":27371237623},{"date":"2026-04-17","current":-81.335146,"twenty":-254.749157,"median":-113.20329,"eighty":-57.943799,"marketCap":27610636203},{"date":"2026-04-24","current":-69.75013,"twenty":-253.791099,"median":-110.250158,"eighty":-58.025793,"marketCap":23679242293},{"date":"2026-04-30","current":-61.379887,"twenty":-252.626844,"median":-107.193308,"eighty":-58.709304,"marketCap":20850663862},{"date":"2026-05-08","current":-65.459145,"twenty":-251.564027,"median":-106.48355,"eighty":-58.020504,"marketCap":22305361341},{"date":"2026-05-15","current":-57.457667,"twenty":-249.188687,"median":-106.083059,"eighty":-57.919993,"marketCap":19630334311},{"date":"2026-05-22","current":-50.784784,"twenty":-247.674355,"median":-104.198267,"eighty":-57.649604,"marketCap":17310899997},{"date":"2026-05-29","current":-41.763424,"twenty":-245.295721,"median":-103.852131,"eighty":-57.457667,"marketCap":14285310527},{"date":"2026-06-05","current":-37.606441,"twenty":-243.995471,"median":-103.234551,"eighty":-55.321243,"marketCap":12882070430},{"date":"2026-06-12","current":-38.299212,"twenty":-239.592317,"median":-102.28828,"eighty":-53.347698,"marketCap":13110504864},{"date":"2026-06-18","current":-33.64261,"twenty":-235.649979,"median":-102.143547,"eighty":-51.161877,"marketCap":11544097313},{"date":"2026-06-26","current":-10.87103,"twenty":-223.802745,"median":-101.125662,"eighty":-50.162538,"marketCap":3712059560},{"date":"2026-07-03","current":-14.085963,"twenty":-220.323597,"median":-100.505297,"eighty":-47.51031,"marketCap":4813439869},{"date":"2026-07-10","current":-12.489761,"twenty":-217.694001,"median":-99.314488,"eighty":-43.652943,"marketCap":4262749714},{"date":"2026-07-17","current":-11.456979,"twenty":-215.893769,"median":-98.774546,"eighty":-42.55123,"marketCap":3924177249},{"date":"2026-07-24","current":-12.133097,"twenty":-213.808047,"median":-93.131819,"eighty":-41.957553,"marketCap":4156690870},{"date":"2026-07-31","current":-11.824868,"twenty":-212.088453,"median":-87.290837,"eighty":-41.541423,"marketCap":4058790398},{"date":"2026-08-07","current":-13.332054,"twenty":-210.416628,"median":-83.155604,"eighty":-40.356892,"marketCap":4585005434},{"date":"2026-08-14","current":-12.237188,"twenty":-208.788963,"median":-82.408413,"eighty":-39.630155,"marketCap":4213799478},{"date":"2026-08-21","current":-12.186563,"twenty":-208.418403,"median":-81.461274,"eighty":-38.522204,"marketCap":4205641106},{"date":"2026-08-24","current":-11.794834,"twenty":-208.418403,"median":-81.335146,"eighty":-38.321611,"marketCap":4068988364}],"updateTime":1787644286862},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02617\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1190623156","title":"藥捷安康-B：Morningside Venture (I) Investments Limited減持，好倉比例降至5.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=1190623156","media":"港股披露","labels":["shareholding"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/1190623156?lang=zh_tw&edition=fundamental","pubTime":"2026-08-24 17:17","pubTimestamp":1787563066,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited于2026年8月20日以每股均价10.5891港元卖出药捷安康-B股份100.00万股，涉资约1058.91万港元。Morningside Venture (I) Investments Limited此次减持前持有药捷安康-B好仓1901.84万股，占比6.08%；减持后持股量为1801.84万股，好仓比例降至5.76%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"药捷安康-B：Morningside Venture (I) Investments Limited减持，好仓比例降至5.76%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136236588","title":"藥捷安康-B（02617）公告將於2026年8月26日召開董事會審議中期業績","url":"https://stock-news.laohu8.com/highlight/detail?id=1136236588","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136236588?lang=zh_tw&edition=fundamental","pubTime":"2026-08-14 17:01","pubTimestamp":1786698081,"startTime":"0","endTime":"0","summary":"药捷安康（南京）科技股份有限公司（02617）8月14日公告，公司董事会已决定于2026年8月26日（星期三）召开董事会会议。\n会议议程包括：  \n(i) 审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计综合中期业绩及其发布；  \n(ii) 研究宣派及派付2026年中期股息（如有）；  \n(iii) 处理其他相关事项。\n公告同时披露，截至公告日期，公司董事会成员包括：执行董事吴永谦博士、吴笛先生；非执行董事贾中新女士；独立非执行董事徐海音女士、冯维波先生及李书湃先生。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123933397","title":"藥捷安康-B：CS Capital Co., Ltd.（國投招商投資管理有限公司）減持，好倉比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1123933397","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123933397?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 17:15","pubTimestamp":1786353342,"startTime":"0","endTime":"0","summary":"CS Capital Co., Ltd.（国投招商投资管理有限公司）于2026年8月7日以每股均价13.74港元卖出药捷安康-B（02617）股份177.30万股，涉资约2436.10万港元。CS Capital Co., Ltd.（国投招商投资管理有限公司）此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143271311","title":"藥捷安康-B：先進製造產業投資基金二期減持，好倉比例降至5.85%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143271311","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143271311?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 17:11","pubTimestamp":1786353064,"startTime":"0","endTime":"0","summary":"Future Industry Investment Fund II (Limited Partnership) (先进制造产业投资基金二期 (有限合伙))于2026年8月7日以每股均价13.74港元卖出药捷安康-B 177.30万股H股，涉资约2436.10万港元。该基金此次减持前持有药捷安康-B好仓2006.33万股，占比6.42%；减持后持股量为1829.03万股，好仓比例降至5.85%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658660504","title":"從0到1，藥捷安康-B（2617.HK）替恩戈替尼上市，以「全球首創」開啓商業化元年","url":"https://stock-news.laohu8.com/highlight/detail?id=2658660504","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658660504?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:37","pubTimestamp":1786322238,"startTime":"0","endTime":"0","summary":"8月6日，药捷安康核心产品替恩戈替尼片（捷恩泰®）获批上市，适应症锁定在既往接受过系统性治疗和FGFR抑制剂治疗、携带FGFR2融合或重排的晚期胆管癌成人患者。","market":"us","thumbnail":"https://img7.gelonghui.com/column/3.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/3.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5971134","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["02617","BK1161","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658671398","title":"藥捷安康首款創新藥獲批，去年股價曾暴升逾600港元，如今已跌破發行價","url":"https://stock-news.laohu8.com/highlight/detail?id=2658671398","media":"红星资本局","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658671398?lang=zh_tw&edition=fundamental","pubTime":"2026-08-09 13:30","pubTimestamp":1786253443,"startTime":"0","endTime":"0","summary":"红星资本局8月9日消息，自去年股价经历“过山车”后，港股创新药公司药捷安康（2617.HK）首款药物获批上市。8月6日，据药捷安康公告，公司自主研发的新药捷恩泰(替恩戈替尼)获国家药监局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体(FGFR)2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608093835908583.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608093835908583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["MEDX","02617","LNGR","159992","06978","BK1161","BK1574","IBBQ","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657660505","title":"藥捷安康-B早盤升逾12% 核心產品替恩戈替尼片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657660505","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657660505?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 09:45","pubTimestamp":1786067100,"startTime":"0","endTime":"0","summary":"模拟交易客户端药捷安康-B早盘高开逾28%，截至发稿，涨幅收窄，股价上涨12.06%，现报12.92港元，成交额2.26亿港元。药捷安康昨晚发布公告称，公司自主研发的1类新药捷恩泰获国家药监局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且具有FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。该疗法此前已获NMPA纳入优先审评及突破性治疗品种。据悉，该药物是药捷安康旗下首款获批上市的创新药。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-07/doc-inimmyem4200035.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126093882","title":"異動解讀｜藥捷安康-B盤中上漲21.51%，核心產品捷恩泰獲NMPA附條件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=1126093882","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126093882?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 09:30","pubTimestamp":1786066241,"startTime":"0","endTime":"0","summary":"8月7日，药捷安康-B盘中上涨21.51%，报14.04港元，成交额2036.61万港元。消息面上，公司8月6日公告，自主研发的1类新药捷恩泰获国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者治疗。此外，替恩戈替尼全球注册性III期临床试验已于7月完成入组，商业化前景进一步明朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨21.51%，核心产品捷恩泰获NMPA附条件批准上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657667795","title":"港股異動 | 藥捷安康-B(02617.HK)高開近15% 核心產品替恩戈替尼片獲批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657667795","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657667795?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 09:24","pubTimestamp":1786065853,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657363981","title":"藥捷安康-B(02617)：捷恩泰®(替恩戈替尼片)獲國家藥品監督管理局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2657363981","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657363981?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 20:06","pubTimestamp":1786018007,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，公司自主研发的1类新药捷恩泰获得国家药品监督管理局附条件批准上市，用于既往接受过系统性治疗和FGFR抑制剂治疗，且具有成纤维细胞生长因子受体2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者的治疗。此前，该疗法获NMPA纳入优先审评及突破性治疗品种。本次捷恩泰获得NMPA附条件批准上市，基于一项在中国开展的多中心、开放性、单臂、II期关键性临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194785171","title":"藥捷安康-B（02617）自主創新藥捷恩泰獲NMPA附條件上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1194785171","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194785171?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 20:06","pubTimestamp":1786017963,"startTime":"0","endTime":"0","summary":"2026年8月6日，药捷安康-B公告称，公司自主研发的1类新药捷恩泰已获国家药品监督管理局附条件批准上市，用于治疗既往接受过系统性治疗和FGFR抑制剂治疗、且携带FGFR2融合或重排的晚期、转移性或不可手术切除的胆管癌成人患者。此前，该产品被NMPA纳入优先审评及突破性治疗品种。药捷安康-B提示，根据上市规则第18A.08条，公司无法保证最终能够成功开发及销售相关产品。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633778","title":"Genecare Development Limited減持藥捷安康-B(02617)46.75萬股 每股作價約12.58港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633778","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633778?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015233,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，8月5日，Genecare Development Limited减持药捷安康-B(02617)46.75万股，每股作价12.5786港元，总金额约为588.05万港元。减持后最新持股数目约为2149.29万股，最新持股比例为6.87%。本交易涉及其他关联方：陈谭庆芬、Ghalibo (PTC) Limited、Morningside Holdings (Asia) Limited、Morningside Bio-Ventures Limited、Morningside Venture (I) Investments Limited。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476921.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121120334","title":"藥捷安康-B：Morningside Holdings (Asia) Limited減持，好倉比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1121120334","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121120334?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:15","pubTimestamp":1786007754,"startTime":"0","endTime":"0","summary":"Morningside Holdings (Asia) Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B（02617）股份46.75万股，涉资约588.05万港元。Morningside Holdings (Asia) Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175707164","title":"藥捷安康-B：Morningside Venture (I) Investments Limited減持，好倉比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1175707164","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175707164?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:14","pubTimestamp":1786007680,"startTime":"0","endTime":"0","summary":"Morningside Venture (I) Investments Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B股份46.75万股，涉资约588.05万港元。Morningside Venture (I) Investments Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126733332","title":"藥捷安康-B：Morningside Bio-Ventures Limited減持，好倉比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126733332","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126733332?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:12","pubTimestamp":1786007572,"startTime":"0","endTime":"0","summary":"Morningside Bio-Ventures Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B（02617）股份46.75万股，涉资约588.05万港元。Morningside Bio-Ventures Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102010843","title":"藥捷安康-B：Ghalibo (PTC) Limited減持，好倉比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102010843","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102010843?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:12","pubTimestamp":1786007559,"startTime":"0","endTime":"0","summary":"Ghalibo (PTC) Limited于2026年8月5日以每股均价12.5786港元卖出46.75万股药捷安康-B股份，涉资约588.05万港元。Ghalibo (PTC) Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180080056","title":"藥捷安康-B：陳譚慶芬減持，好倉比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180080056","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1180080056?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:12","pubTimestamp":1786007557,"startTime":"0","endTime":"0","summary":"陈谭庆芬于2026年8月5日以每股均价12.5786港元卖出药捷安康-B（02617）股份46.75万股，涉资约588.05万港元。陈谭庆芬此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139351553","title":"藥捷安康-B：Genecare Development Limited減持，好倉比例降至6.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139351553","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139351553?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 17:11","pubTimestamp":1786007507,"startTime":"0","endTime":"0","summary":"Genecare Development Limited于2026年8月5日以每股均价12.5786港元卖出药捷安康-B股份46.75万股，涉资约588.05万港元。Genecare Development Limited此次减持前持有药捷安康-B好仓2196.04万股，占比7.02%；减持后持股量为2149.29万股，好仓比例降至6.87%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122953396","title":"異動解讀｜藥捷安康-B盤中上漲5.08%，密集回購疊加多管線臨床進展推動股價延續反彈","url":"https://stock-news.laohu8.com/highlight/detail?id=1122953396","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122953396?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 09:43","pubTimestamp":1785980635,"startTime":"0","endTime":"0","summary":"8月6日，药捷安康-B盘中上涨5.08%，报12.26港元，成交额4650.54万港元，延续近日强势反弹态势。消息面上，公司自7月以来密集回购H股，7月内累计回购71.8万股，合计耗资逾700万港元，释放管理层对公司价值的信心。同时，公司于7月24日向67名员工授出约525.89万股H股激励，进一步绑定核心团队利益。管线方面，公司核心产品替恩戈替尼全球注册性III期临床试验已完成入组，TT-00973及TT-01488两款产品II期临床亦先后获批开展，多管线推进提升市场预期。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨5.08%，密集回购叠加多管线临床进展推动股价延续反弹","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169653122","title":"異動解讀｜藥捷安康-B盤中上漲8.83%，港股創新藥板塊持續走強疊加公司密集回購","url":"https://stock-news.laohu8.com/highlight/detail?id=1169653122","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169653122?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 09:52","pubTimestamp":1785894767,"startTime":"0","endTime":"0","summary":"8月5日，药捷安康-B盘中上涨8.83%，报12.7港元，成交额8113.72万港元，延续前一交易日强势反弹态势。消息面上，港股创新药板块近日集体走强，内资持续加仓创新药标的，外资亦有布局。公司层面，药捷安康自7月以来密集回购H股，7月内累计回购71.8万股，合计耗资逾700万港元，释放管理层对公司价值的信心。此外，公司于7月24日向67名员工授出约525.89万股H股激励，进一步绑定核心团队利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"药捷安康-B盘中上涨8.83%，港股创新药板块持续走强叠加公司密集回购","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":129,"code":"91000000","status":"200"}]}}